LegoChem Biosciences announced on the 27th that it has signed a technology transfer contract with Iksuda for joint development of a new anti-cancer drug candidate LCB14. The contract is worth up to $1 billion (about 1.2 trillion won). With this contract, LegoChem Biosciences secured $50 million (about 60 billion won) in advance payments and short-term milestones. Milestones according to the development, permission, and commercialization stages are up to $950 million.

Iksuda will have the right to develop and commercialize LCB14 globally except for China and Korea. LegoChem Biosciences will jointly conduct clinical trials in the United States with Iksuda in a way that pays part of the initial clinical cost.